[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemophagocytic-lymphohistiocytosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemophagocytic-lymphohistiocytosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100497853","phase-2-ruxolitinib-as-first-line-treatment-in-primary-haemophagocytic-lymphohistiocytosis-r-hlh-100497853",false,"NCT05762640","Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)","Efficacy of Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (HLH) in Children: a Phase 2, Multicentre, Non-comparative Study","R-HLH","Inclusion Criteria\n\n* Patient aged 0 to 22 years\n* Patient with HLH syndrome confirmed by at least one of the two criteria:\n\n  1. Confirmed genetic diagnosis of a condition predisposing to primary HLH (see table 1 and table 2) or abnormal expression of perforin, MUNC13-4, SAP or XIAP in FACS and\u002For positive family history OR\n  2. Presence of at least 5 of the 8 following HLH diagnostic criteria:\n* Fever\n* Splenomegaly\n* Cytopenia (affecting at least two cell lineages)\n* Haemoglobin \\\u003C 9 g\u002Fdl (\\\u003C10 g\u002FdL in neonates)\n* Platelets \\\u003C 100,000\u002FµL\n* Absolute neutrophil count (ANC) \\\u003C 1,000\u002FµL\n* Hypertriglyceridemia and\u002For hypofibrinogenemia\n* Fasting triglycerides ≥ 3 mmol\u002Fl\n* Fibrinogen \\\u003C1.5 g\u002FL\n* Haemophagocytosis found in a histological sample (without evidence of a malignant process or an underlying rheumatic disorder)\n* Decreased or absent NK function\n* Ferritin ≥ 500 µg\u002Fl\n* Presence of activated T cells in the immune phenotyping as evidenced by expression of the activation marker DR (superior to the normal value of the laboratory) OR CD25 soluble (sIL-2 receptor) ≥ 2,400 U\u002FmL.\n* Patient with no previous specific treatment for HLH syndrome\n* For patients of childbearing age : using an effective method of contraception during the trial, and through to 90 days after EOS for male participants and 30 days after EOS for female participants\n* Freely given, informed and written consent of legal representative of the participant or consent of the adult participant\n* Affiliation to Social Security.\n\nExclusion Criteria\n\n* Previous treatment with ATG, Alemtuzumab, Etoposide, JAK-inhibitors, rifampicin and\u002For anti-Interferon gamma antibodies. St. John's Wort, or any other strong CYP3A4 inducers.\n* Previous treatment with corticosteroids and\u002For cyclosporine A for more than 14 days\n* Isolated CNS disease.\n* Contraindication to receive Ruxolitinib:\n* History of hypersensitivity to the active substance or to any of the excipients\n* Pregnant or lactating female patient\n* Contraindication to receive methylprednisolone or prednisolone\n* History of hypersensitivity to the active substance or to any of the excipients\n* Any infectious condition with the exception of infections, which are the trigger for lymphohistiocytic activation.\n* Patient with acute very severe renal impairment (Creatinine Clearance \\\u003C15 mL\u002Fmin\u002F1.73m²) who are NOT receiving dialysis.\n* Patient with Grade 4 hepatic failure according to the CTCAE v5.0 of 27 November 2017 (Life-threatening consequences; moderate to severe encephalopathy; coma)\n* Past or know active tuberculosis\n* Known rheumatologic disorder.\n* Known active malignancy.\n* Patient who is taking another investigational agent or is enrolled in another treatment protocol.\n* Patient who cannot tolerate administration of drugs PO or through NG","ALL","22 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this project is to study the survival of patients until Haematopoietic Stem Cell Transplantation following the use of Ruxolitinib as first-line treatment associated to corticosteroids in primary HLH.",[27],"Haemophagocytic Lymphohistiocytosis",[27,29,30,31],"Lymphohistiocytic activation syndrome","Ruxolitinib","Jakavi","RECRUITING","2026-04-20",{"date":35,"type":36},"2026-04-23","ACTUAL",{"date":38,"type":36},"2024-11-10",{"date":40,"type":21},"2028-03",{"name":42,"class":43},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100493234","assessing-the-presence-of-ct-dna-in-lymphoma-associated-hlh-100493234","NCT05702502","Assessing the Presence of CT-DNA in Lymphoma Associated HLH","Liquid Biopsy for the Identification of Malignancy Associated Haemophagocytic Lymphohistiocytosis (HLH)","Inclusion criteria:\n\n* Informed consent.\n* Age ≥18 years.\n* Clinically confirmed HLH.\n* High dose steroids and\u002For systemic anti-cancer therapy (SACT) for \\\u003C72 hours for the current episode of HLH (anakinra is not considered SACT). Prior steroid use \\>14 days at the time of consent is permitted.\n* Patients with recurrent HLH may be included.\n* Patients already known to have underlying lymphoma, or have relapsed lymphoma may be included.\n\nExclusion criteria:\n\n• Cause of HLH already known to be due to a non-malignant cause.","18 Years",{"count":54,"type":21},12,"OBSERVATIONAL","Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose. The most common cause of HLH in adults is lymphoma (blood cancer). Outcomes for adults with HLH and cancer are serious, and most die after days or weeks because they have been diagnosed or treated too late. It is likely that many cases where patients died of HLH with no underlying cause actually had cancer.\n\nRecently it has been found that patients with certain types of lymphoma have DNA which comes directly from their cancer (circulating tumour DNA; ctDNA). Aggressive lymphomas release a lot of ctDNA which can be detected in the blood of patients. This study will look for ctDNA in patients with HLH, and see if it is possible to use it to diagnose lymphoma earlier. Patients will provide a small additional blood sample for analysis. Diagnosing lymphoma more rapidly would mean more people could get the correct treatment for the lymphoma which has caused their HLH. They could receive the correct treatment sooner. Earlier diagnosis and treatment could improve survival for these patients.",[58,27],"Lymphoma","2025-04-04",{"date":61,"type":36},"2025-04-08",{"date":63,"type":36},"2023-06-30",{"date":65,"type":21},"2026-01-01",{"name":67,"class":43},"Nottingham University Hospitals NHS Trust",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100572542","the-microbiome-in-blood-cancer-and-hlh-100572542","NCT06734624","The Microbiome in Blood Cancer and HLH","Using Blood and Stool Samples From Patients With Blood Cancer and\u002For Haemophagocytic Lymphohistiocytosis to Study the Influence of Host Microbial Factors on Toxicity and Survival","Inclusion Criteria:\n\n* Informed consent\n* Age 16-100 years\n* A blood cancer or clinically confirmed HLH by H-score criteria\n\nExclusion Criteria:\n\n* Known positive HIV, hepatitis B and\u002For hepatitis C serology (as laboratory not accredited to handle high-risk samples).\n* Active communicable disease eg SARS-CoV-2, monkeypox.","16 Years","100 Years",{"count":78,"type":21},750,"The bacteria and viruses in the bowel (gut microbiota; GM) have powerful effects on the immune system. GM changes are seen in patients with auto-immune diseases, where the immune system attacks normal tissues, and cancer, and for those with some forms of blood cancer, and appears to affect both responses to, and side-effects of treatment. The investigators want to examine the GM and the associated small molecules (metabolites) in adults with different forms of blood cancer, particularly those undergoing immunotherapy, those with have newly diagnosed follicular lymphoma, and also those with a severe hyperinflammatory disorder which causes problems similar to sepsis called Haemophagocytic lymphohistiocytosis (HLH), which is also often caused by an underlying lymphoma. The investigators want to collect blood and stool samples from patients and use the results of tests already performed in the NHS as well as recording how well patients responded to treatment. The samples will be used to identify novel targets within the GM and associated metabolites which contribute to side effects of, or response to immunotherapy, or are responsible for causing HLH which can be targeted to make treatment better tolerated. For patients with newly diagnosed indolent lymphoma the aim is to see if there are differences which may account for patients needing early or late treatment, or no treatment ever.",[81,82,27],"Diffuse Large B Cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)",[84,85,86,87],"Microbiome","DLBCL","FL","HLH","NOT_YET_RECRUITING","2024-12-12",{"date":91,"type":36},"2024-12-16",{"date":93,"type":21},"2025-01-01",{"date":95,"type":21},"2044-12",{"name":97,"class":43},"University of Nottingham"]